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Abstract
Serrated adenomas form a distinct subtype of colorectal pre-malignant lesions that may progress to malignancy along a
different molecular pathway than the conventional adenoma-carcinoma pathway. Previous studies have hypothesised that
BRAF mutation and promoter hypermethylation plays a role, but the evidence for this is not robust. We aimed to carry out a
whole-genome loss of heterozygosity analysis, followed by targeted promoter methylation and expression analysis to
identify potential pathways in serrated adenomas. An initial panel of 9 sessile serrated adenomas (SSA) and one TSA were
analysed using Illumina Goldengate HumanLinkage panel arrays to ascertain regions of loss of heterozygosity. This was
verified via molecular inversion probe analysis and microsatellite analysis of a further 32 samples. Methylation analysis of
genes of interest was carried out using methylation specific PCR (verified by pyrosequencing) and immunohistochemistry
used to correlate loss of expression of genes of interest. All experiments used adenoma samples and normal tissue samples
as control. SSA samples were found on whole-genome analysis to have consistent loss of heterozygosity at 4p15.1–4p15.31,
which was not found in the sole TSA, adenomas, or normal tissues. Genes of interest in this region were PDCH7 and SLIT2,
and combined MSP/IHC analysis of these genes revealed significant loss of SLIT2 expression associated with promoter
methylation of SLIT2. Loss of expression of SLIT2 by promoter hypermethylation and loss of heterozygosity events is
significantly associated with serrated adenoma development, and SLIT2 may represent a epimutated tumour suppressor
gene according to the Knudson ‘‘two hit’’ hypothesis.
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Introduction
Serrated adenomas are a type of colorectal polyp [1] that
possess features of both hyperplastic and adenomatous polyps. The
classical feature of serrated adenomas is saw-toothed infolding of
dysplastic colonic epithelium as described by Longacre et al (2).
The classification of serrated adenomas into distinct types has
presented a challenge. Snover et al [2] suggested subdivision into
sessile serrated adenoma (SSA), traditional serrated adenoma
(TSA), mixed serrated polyp (MSA) and sessile serrated polyp
(SSP), with the latter two subtypes being reserved for difficult to
classify or atypical mixed polyps with serrated morphology. Rex et
al [3] suggested polyps be subdivided into SSA/P (with or without
cytological dysplasia), TSA and stated that these two lesions were
the predominant pre-malignant lesions in the serrated pathway.
They also stated that dysplasia observed in SSA/P represented the
progression of a SSA towards malignancy. The differences
between SSAs and TSAs were examined by Torlakovic et al [4]
who described SSAs as flat, sessile lesions with crypts that grow
parallel to the muscularis mucosae and highly variable and
irregular Ki67 expression, whereas TSAs are pedunculated lesions
with similar crypts to SSA but low Ki67 expression and a highly
eosinophillic cytoplasm. SSA are thought to form a unique subset
of colorectal polyps with a distinct molecular pathogenic pathway,
known as the ‘‘serrated pathway’’.
The hypothesised molecular pathway in the development and
progression of SSA is thought to be different from the
conventional adenoma-carcinoma pathway. The most important
molecular event known to be highly frequent in the pathogenesis
of SSAs is an activating mutation in BRAF (1). Multiple studies
have found BRAF mutations within SSAs at frequencies of 62–
100% [5–8]. However, BRAF mutations are not specific to
serrated tumours, also being found in colonic adenomas and
cancers without a serrated morphology [9]. Also, BRAF mutations
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have been found in TSA with dysplasia at a high frequency [10].
Consequently BRAF mutations in isolation cannot be said to cause
sessile serrated morphology. It has been proposed that a
hyperplastic polyp (HP) is initiated by a BRAF mutation. The
HP then acquires the CpG island methylator (CIMP) phenotype,
leading to silencing of genes such as IGFBP7 and MLH1. This is
accompanied or followed by progression to a SSA. Methylation of
the MLH1 promoter is also hypothesised to be responsible in part
for the acquisition of microsatellite instability and for progression
to microsatellite-unstable cancer. However, a set of BRAF-mutant,
CIMP-high, microsatellite stable cancers also exists [1] and the
origins of this type of tumour are currently unknown.
Since the serrated adenoma molecular pathway is not fully
elucidated, and is unknown whether a common pathway exists to
give the serrated phenotype, which then leads to the formation of
SSA or TSA, we used genome-wide SNP typing to screen for
regions of copy number change and loss of heterozygosity in a set
of sessile serrated adenomas. On the basis of our results, we
investigated candidate genes in regions of loss of heterozygosity for
promoter methylation and changes in expression.
Results
Of the 42 total serrated adenomas, 20/42 were from male
patients, and 22/42 from female patients. The median age of
patients was 69 years (range 34–87 years). In terms of location, 8/
42 were located in the caecum, 2/42 in the ascending colon, 11/
42 in the sigmoid colon and 21/42 in the rectum. Of the forty two
serrated adenomas, 1/42 was a mixed traditional serrated & sessile
serrated adenoma, 1/42 was a mixed sessile serrated/tubovillous
adenoma (reported predominantly as a sessile serrated adenoma),
3/42 were filiform TSA [3] and the remaining 37/42 were sessile
serrated adenomas. In terms of levels of dysplasia, the mixed SSA/
Adenoma was mildly dysplastic, and of the 37 SSA, 19 had mild
dysplasia and 18 had no dysplasia. We divided the SA’s into two
sets, an initial discovery set consisting of 10 SA’s (9 SSA, 1 TSA)
and a second verification set consisting of 32 SA’s (2 TSA, 1 mixed
SSA, 29 SSA).
In the classical adenoma samples, 6/10 were from female
patients and 4/10 from male patients, with a median age of 58
years (range 45–73 years). They were located in the sigmoid colon
(2/10), Caecum (3/10) and Descending colon (2/10) and rectum
(3/10). In the classical adenoma tissue microarray there were 100
samples, of which 45/100 were from male patients and 55/100
from female patients with a median age of 58 years (range 30–85
years). In terms of histology, 55/100 were mildly dysplastic, 40/
100 moderately dysplastic and 5/100 severely dysplastic. Of the
100 polyps on the array, 22/100 were located in the rectum, 25/
100 in the sigmoid, 10/100 in the descending colon, 21/100 in the
transverse colon, 10/100 in the ascending colon and 12/100 in the
caecum.
The initial ten serrated adenoma samples (9 SSA, 1 TSA) from
the discovery set were successfully genotyped on the Goldengate
array. Of the 9 SSA, 4 had dysplasia and 5 did not. The average
genotyping call rate was 0.993. Samples were assessed for copy
number changes and LoH events using the log R ratio and the B
allele frequency in Illumina GenomeStudio software. There were
no large-scale chromosomal gains or losses, except for one sample
where there was copy-neutral LoH for the majority of the p-arm of
chromosome 6 (Figure 1). There was only one recurrent region of
small-scale copy number change (Figure 2), a single-copy deletion
at chromosome 4p15.1–4p15.31 (Chr4:19,837,583–33,138,129).
Nine out of ten samples (all SSA samples, with and without
dysplasia) demonstrated this region of copy neutral LoH and this
result was confirmed by MIP array analysis in the single SSA
sample for which the assay was successful. In total 2 SSA samples
were analysed via MIP array with 1 sample failing due to
insufficient sample quality. Due to cost constraints the whole
genome genotyping was not repeated on the subsequent 32
samples of the verification set. The sole SA in the discovery set
which GoldenGate array analysis did not demonstrate LoH at
4p15.1–15.31 was the SA classified as a TSA.
In order to validate the SNP array data, microsatellite LOH
analysis was performed on the 9 initial SSA samples (SA A - I) in
the discovery set (specifically excluding the single TSA sample).
The results of this are shown in Table 1, as well as the measured
heterozygosity at these loci, the genetic and cytogenetic position
and BP length of the microsatellite. Although there was variable
performance of markers and hence LOH frequency, presumably
related to chance differences in allelic amplification from FFPE-
derived DNA, LOH in the region was confirmed. Although there
was no normal tissue we noted that all SSA samples appeared to
be homozygous. We could not distinguish this between acquired
and constitutional homozygosity however the initial samples
matched with the SNP arrays so we assume this represented
acquired homozygosity. In the sessile serrated adenoma samples of
the discovery set, AFM112XD4 was found to show LOH in all 9
samples except sample C. Being the most informative marker in
the region, AFM112XD4 was used to test LOH in the second
verification set of 32 SAs. Within this group, of the 29 SSA’s, 26/
29 had LOH (89.7%). The mixed SSA also demonstrated LOH,
whereas the 2 TSA’s did not demonstrate LoH, giving a total of
twenty-seven of 32 (87%) samples showing LOH. This was
significantly different to the observed rate of heterozygosity in the
blood control samples (78% heterozygosity, p,0.001, Z=26.930,
Rank sum). This also reassured us that the observed homozygosity
was highly likely to be acquired rather than constitutional. None of
the 10 classical adenoma samples had LoH at this marker.
In this region of LoH there are 7 genes: SLIT2
(ENSG00000145147), GPR125 (ENSG00000152990), PACRGL
(ENSG00000163138), DHX15 (ENSG00000109606), SOD3
(ENSG00000109610), RBPJ (ENSG00000168214) and PCDH7
(ENSG00000169851). Of these, we prioritised two genes – SLIT2
and PCDH7 – as candidate LOH targets, based on their functions.
Author Summary
Polyps in the bowel are the precursors of development of
bowel cancer. Much is known about the biology and
pathology of these polyps. These polyps have classically
been divided into two main types: adenomas and
hyperplastic polyps. The former has pre-malignant poten-
tial, whereas it is thought the second does not. Within the
last 10 years, a third type of polyp has been discovered,
called the ‘‘serrated adenoma,’’ that has features of both
adenomas and hyperplastic polyps. However, they seem to
have very different characteristics, and we are not certain
of the distinct molecular event that leads to their
development. In this study we investigate the genetic
differences that set apart serrated adenomas from other
types of polyps. We report on a gene change within these
polyps that seems to be associated with their develop-
ment. The gene change is highly unusual as it consists of
the loss of one copy of the gene as well as methylation of
the other gene. This methylation switches off the remaining
copy of the gene and stops its associated protein from
being expressed in the polyp. To our knowledge, this is the
first time this phenomenon has been seen.
SLIT2 Loss Asssociated with Serrated Adenomas
PLOS Genetics | www.plosgenetics.org 2 May 2013 | Volume 9 | Issue 5 | e1003488
SLIT2 is a negative regulatory component of the DCC/netrin
pathway (14) which leads to malignant transformation in colorectal
epithelial cells by Hakai-mediated E-cadherin degradation
[11,12], and PCDH7 encodes a protocadherin, the C-isoform of
which interacts with ATM in double strand break repair (15).
Methylation specific PCR of the PCDH7 and SLIT2 promoter
regions was carried out in the verification group only. No further
examination of other gene specific promoter regions in this area
(i.e. GPR125,PACRGL,DHX15,SOD3 or RBPJ) was carried out as a
visual examination of the ENCODE DNA methylation tracks in
the UCSC Genome Browser did not suggest any long range
methylation in this region. For PCDH7, 12/32 (37.5%) SAs had
methylation (12/29 SSAs, 0/1 mixed SSA/TSA, 0/2 TSA),
whereas none of the classical adenoma (0/10) samples and 1/5
(20%) of the normal mucosa samples were methylated (Figure 2).
For SLIT2, 31/32 (96.9%) SAs had methylation (29/29 SSA’s, 1/1
mixed TSA/SSA, and 0/2 TSAs). There was no methylation in
the adenoma (0/10) or normal mucosa samples (0/5) (Figure 3).
No methylation analysis of additional normal mucosa samples was
carried out at this point as the frequency of methylation observed
in SLIT2/PCDH7 was so low it was thought unlikely to add any
additional information. The MSP result was verified in a limited
subset of samples using pyrosequencing. Five CpG dinucleotides
were interrogated in the pyrosequencing PCR, based on the
coverage of the MSP, and abnormal methylation was defined as a
methylation percentage greater than two times the standard
deviation of the average methylation in normal mucosa. It was
found that in SSAs, there was consistent and informative promoter
methylation at the 2nd, 3rd and 4th CpG’s within the MSP region
(Table 2). There was no hypermethylation in a caecal polyp, nor in
normal mucosa. As part of a separate experiment conducted in the
laboratory, it was found that there was hypermethylation in SLIT2
within a panel of cell lines (Table 2). Using a separate
pyrosequencing primer for SLIT2 (PM00018634) , the SSA were
checked for long range methylation in the serrated adenomas
further down the CpG island. There was no methylation seen
(Table 2).
In analysis of BRAF mutation status, 30/42 (73.1%) of analysed
serrated adenomas were BRAF mutant, with 29/41 being V600E
and 1/41 being V600L, in line with previous studies. Of the three
TSA within the SA group, two had V600E mutations and the
other was wild type and in the SSA group, 27/41 had BRAF
mutations.
To study the relationship between methylation and expression
in serrated adenomas, IHC for PCDH7 and SLIT2 was carried
out on the 32 SAs within the verification group. For PCDH7
expression, 23/32 (72.0%) SA samples (23 SSA only) scored either
a median expression level of 1 or 0 (minimal/no expression), and
9/32 (28.1%) had normal expression (6 SSA, 1 mixed TSA/SSA,
2 TSA), very similar to the control normal mucosa. For SLIT2,
31/32 (97%) SA samples (29/29 SSA, 1 mixed TSA/SSA and 1
TSA) had a median expression score of 1 or 0 (minimal/no
expression), and 1/32 (3%) had normal expression (1 TSA). Inter-
observer variation for PCDH7 expression was k=0.70 (SE=0.12,
Z= 5.60, p,0.001) and for SLIT2 expression k=0.74
(SE= 0.16,Z= 4.53, p,0.001). Of the SLIT2 samples, there was
only 1 sample where there was disagreement between examiners,
with examiner one scoring it as 2/3 and examiner two as 3/3.
After discussion, the score for this sample was set at 3/3.
In Figure 4a (56 magnification) & 4b (56, 106, 206
magnification), normal expression of SLIT2 can be seen in both
the conventional adenoma and normal tissue, whereas there is
complete loss of expression in the serrated adenoma. A particularly
interesting result was found in a polyp with mixed adenomatous/
serrated architecture, as demonstrated in Figure 5. In this image,
there was very reduced expression of SLIT2 within the crypts with
Figure 1. Region of CN-LoH in Chromosome 6 in sample SA2 (specific area illustrated by red box). The plot below demonstrates a loss of
heterozygosity in this region shown by the loss of heterozygous SNPs with a B allele frequency of ,0.5, with only homozygous SNPs remaining. This
event is copy-neutral because there is no change in the Log R ratio seen in the corresponding plot.
doi:10.1371/journal.pgen.1003488.g001
Figure 2. LRR and BAF plot of region of CN-LOH within serrated adenomas. Red dotted line in B-allele frequency plot indicates region of
CN-LOH; Red box indicates chromosomal position within ideogram.
doi:10.1371/journal.pgen.1003488.g002
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serrated morphology but normal expression of SLIT2 within
the crypts with ‘‘classical’’ adenomatous morphology.
There was a poor correlation between PCDH7 promoter
methylation and expression (Table 3), in SA, normal and
classical adenoma tissues (n = 47) suggesting that there may be
no relationship between the two (Fisher’s exact test,
p = 0.478). By contrast, there was a clear positive association
between SLIT2 methylation and loss of expression (Fisher’s
exact test, p = 4.9761029, Table 3). Similarly, in comparing
PCDH7 expression vs. LOH at AFM112XD4 (Table 4), in
samples where there was loss of PCDH7 expression there was
significantly higher rates of LOH at AFM112XD4 (Fishers
exact p= 0.001). In comparing SLIT2 expression vs. LOH at
AFM112XD4 (Table 4), in samples where there was loss of
SLIT2 expression there was significantly higher rates of LOH
at AFM112XD4 (Fishers exact p = 5.16610-9).
For the classical adenomas on the tissue microarray, 83/85
(97.6%) demonstrated strong expression of PCDH7, and 2/85
(2.4%) loss of expression. For SLIT2, 4/83 (4.8%) had a
median expression score of either 1 or 0 (minimal/no
expression) and 79/83 (95.2%) had normal expression.
As part of a separate independent study [13] conducted in
our laboratory into whole genome methylation patterns
comparing paired colorectal tumour and normal mucosa a
gene set enrichment analysis (GSEA) was carried out
comparing tumour vs. normal mucosa. On leading edge
analysis (an analysis designed to ascertain the most frequently
differentially methylated genes within a gene set) of the
GSEA, SLIT2 was the most highly ranked gene in the set.
This suggests SLIT2 may be implicated as a tumour
suppressor in colorectal carcinogenesis.
Discussion
A consistent and specific region of LOH occurs in both
sessile serrated adenomas (irrespective of presence/absence of
dysplasia), located around chromosome 4p15.1–4p15.31 (Chr
4:18,500,000–34,000,000). Of two excellent candidate genes
within this region, SLIT2 shows very frequent promoter
methylation and low protein expression. The other gene,
PCDH7, is not infrequently methylated, but shows no
convincing evidence of reduced protein expression, and the
association between methylation and expression is weak. It is
conceivable that long range methylation may be occurring
within this region, causing promoter methylation in a number
of genes. However, there is no concordance between SLIT2 &
PCDH7 methylation and so we thought that this was unlikely.
A potential weakness of our study is the use of methylation
specific PCR in analysing promoter methylation. As discussed
in the methods, we felt that MSP provided a reasonable
balance between cost and sensitivity, and we took all possible
methods to reduce false positives. We verified the MSP using
bisulfite pyrosequencing in a limited sample set, finding
informative methylation within the SLIT2 region studied. We
were also reassured by the lack of methylation observed in
both normal mucosa and classical adenoma samples, and the
fact there was no long range methylation of SLIT2 outside the
identified region.
Alterations in the chromosome 4p15 region have been
identified in a variety of cancers. Shivapurkar et al [14]
demonstrated a LOH rate of 47% in 4p15 using microsatellite
markers in a panel of colorectal cancers. In a separate study
[15], they also demonstrated LoH in this region in 57% of
breast cancers studied. This finding was also replicated [16] in
T
a
b
le
1
.
M
ic
ro
sa
te
lli
te
Lo
H
st
at
u
s
b
y
m
ar
ke
r
an
d
b
y
sa
m
p
le
(o
rd
e
re
d
fr
o
m
le
ft
to
ri
g
h
t
b
y
p
o
si
ti
o
n
).
S
a
m
p
le
D
4
S
2
3
0
D
4
S
4
1
8
D
4
S
9
1
4
D
4
S
3
1
3
D
4
S
6
1
6
D
4
S
1
5
9
3
D
4
S
2
2
8
9
A
F
M
1
1
2
X
D
4
SS
A
-A
N
o
Lo
H
N
o
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
SS
A
-B
Lo
H
Lo
H
Lo
H
Lo
H
N
o
Lo
H
Lo
H
N
o
Lo
H
Lo
H
SS
A
-C
N
o
Lo
H
N
o
Lo
H
Lo
H
N
o
Lo
H
Lo
H
N
o
Lo
H
N
o
Lo
H
Lo
H
SS
A
-D
Lo
H
Lo
H
Lo
H
Lo
H
N
o
Lo
H
Lo
H
Lo
H
Lo
H
SS
A
-E
N
o
Lo
H
Lo
H
Lo
H
Lo
H
N
o
Lo
H
Lo
H
Lo
H
Lo
H
SS
A
-F
Lo
H
Lo
H
Lo
H
Lo
H
N
o
Lo
H
Lo
H
N
o
Lo
H
Lo
H
SS
A
-G
N
o
Lo
H
N
o
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
SS
A
-H
Lo
H
Lo
H
Lo
H
Lo
H
N
o
Lo
H
N
o
Lo
H
N
o
Lo
H
Lo
H
SS
A
-I
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
Lo
H
T
o
ta
l
Lo
H
5
5
.6
%
6
6
.7
%
1
0
0
%
8
8
.9
%
4
4
.4
%
7
7
.8
%
5
5
.6
%
1
0
0
%
Lo
ca
ti
o
n
(B
P
)
ch
r4
:2
8
2
4
8
4
5
1
-2
8
2
4
8
8
0
8
ch
r4
:2
8
9
7
4
3
0
7
-
2
8
9
7
4
6
5
6
ch
r4
:3
0
3
6
8
6
5
2
-
3
0
3
6
8
9
5
9
ch
r4
:2
7
2
9
7
3
3
1
-
2
7
2
9
7
7
1
4
ch
r4
:2
3
1
5
7
4
7
9
-
2
3
1
5
7
8
5
4
ch
r4
:2
0
8
5
3
5
0
2
-
2
0
8
5
3
8
6
7
ch
r4
:1
9
2
9
9
8
5
0
-
1
9
3
0
0
2
7
9
ch
r4
:3
0
3
6
4
8
3
3
-
3
0
3
6
4
9
9
8
C
yt
o
b
an
d
4
p
1
5
.1
4
p
1
5
.1
4
p
1
5
.1
4
p
1
5
.2
4
p
1
5
.2
4
p
1
5
.3
1
4
p
1
5
.3
1
4
p
1
5
.1
B
P
Si
ze
1
9
1
–
2
1
7
2
1
0
–
2
2
6
1
3
2
–
1
3
3
2
4
2
–
2
4
3
2
2
5
–
2
2
6
1
3
8
–
1
5
4
2
8
4
1
3
2
G
e
n
e
s
-
-
P
C
D
H
7
-
-
K
C
N
IP
4
-
P
C
D
H
7
,
SL
IT
2
M
e
as
u
re
d
h
e
te
ro
zy
g
o
si
ty
5
6
.3
%
8
7
.5
%
4
1
.0
%
8
1
.3
%
8
3
.3
%
4
5
.8
%
6
2
.5
%
7
8
.0
%
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
g
e
n
.1
0
0
3
4
8
8
.t
0
0
1
SLIT2 Loss Asssociated with Serrated Adenomas
PLOS Genetics | www.plosgenetics.org 4 May 2013 | Volume 9 | Issue 5 | e1003488
a study of malignant mesotheliomas and small cell lung cancer
(.50%). However, these findings may have been by aneuploidy
that is commonly found in these types of cancer, whereas all our
SAs were near-diploid as assessed by SNP arrays.
SLIT2 has been postulated for several years to act as a tumour
suppressor gene in several cancers [17]. On the basis that SLIT2
expression is regulated by methylation, the findings of our
experiment agree with those of Dallol et al [18]. They examined
the role of SLIT2 as a tumour suppressor in a panel of 32
colorectal cancers, finding that 23 (72%) were methylated in this
region. Furthermore, after treatment of 6 colorectal cancer cell
lines with the demethylation agent 5-aza-2-deoxycytidine (5-aza-
C), they demonstrated re-expression of SLIT2. In order to
ascertain whether SLIT2 acted as a tumour suppressor, Dallol et
al exposed colorectal cancer cell lines to ectopic SLIT2, finding
that it could suppress colony formation.
The mechanism by which SLIT2 exerts pro-apoptotic and
growth-suppressive effects is unclear. Prasad et al [19] suggested
that SLIT2 regulates the b-catenin and PI3K signalling pathways
and enhances b-catenin/E-cadherin-mediated cell adhesion. The
pro-apoptotic role of SLIT2 may be caused by interaction with the
DCC pathway, as SLIT2 interacts with ROBO [20] which in turn
interacts with DCC (20), with apoptosis occurring via the caspase
pathway [21]. A recent study [22] has also identified low
frequency SLIT2 methylation as a marker of high risk dysplasia
in ulcerative colitis cancers.
This study is the first to demonstrate SLIT2 LOH, promoter
methylation and down-regulation consistently occurring in a pre-
malignant lesion (the sessile serrated adenoma), and may explain
partially the alternate pathway by which sessile serrated adenomas
progress towards carcinoma. We did observe a single TSA where
there was loss of SLIT2 expression without LOH or SLIT2
promoter methylation. This could be because of somatic mutation
within SLIT2, although this was not examined due to the excessive
cost of sequencing SLIT2. Whilst further studies are required to
show a causal relationship between loss of SLIT2 expression and
the pathogenesis of SAs, in principle, the two hits we have found at
SLIT2 – methylation and LOH – could promote tumorigenesis by
a revised version of the Knudson two hit hypothesis [23], in which
LOH renders an epimutation homozygous.
Materials and Methods
Forty-two formalin-fixed, paraffin-embedded (FFPE) serrated
adenomas were obtained from Mayday University Hospital,
Gloucester NHS Hospitals Foundation Trust and St George’s
Hospital, London NHS Trust. All patients had had colonoscopy
for screening purposes and none reported a family history of
colorectal cancer. Representative haematoxylin and eosin-stained
sections were reviewed independently by two consultant histopa-
thologists to confirm serrated architecture and the presence/
absence of dysplasia. 100 ‘‘classical’’ adenomas from patients
undergoing screening colonoscopy, but without a family history of
cancer, were examined using a tissue microarray. Normal tissue
samples were obtained from 10 unrelated patients. All mucosa
samples sample from patients undergoing screening colonoscopy
for a change in bowel habit who did not have a family history of
cancer, no polyps on colonoscopy and on biopsy were found to
have completely normal histological appearances, without any
mucosal inflammation being present. Ethical approval was
obtained from Wandsworth Ethics Committee (07/H0806/109)
and Oxford Research Ethics Committee (05/Q1605/66). 40 mM
tissue scrolls were cut and DNA extraction was performed using
proteinase K digestion at 55uC. DNA was diluted to a
concentration of 50 ng/ml.
Genome-wide SNP genotyping was carried out using the
Illumina Goldengate HumanLinkage system (Panel V) on 10
serrated adenoma samples of which 9/10 were sessile serrated
adenomas and 1/10 was a traditional serrated adenoma (TSA).
This was included to see if the SSA and TSA demonstrated similar
Figure 3. Example gel image of PCDH7 promoter methylation-
specific PCR (top gel) and SLIT2 methylation-specific PCR
(bottom and middle gels). MSP reactions row refers to wells for the
methylated and unmethylated reactions for the methylation specific
PCR. Methylation status refers to the final determination of methylation
within each serrated adenoma sample. Row key: MSP reactions –
M=methylation specific reaction, U= unmethylated specific reaction;
Methylation status – M=methylated, U = unmethylated.
doi:10.1371/journal.pgen.1003488.g003
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characteristics. Briefly, 1 mg of genomic DNA was amplified as per
the manufacturer’s instructions and hybridised to the Sentrix
BeadArray overnight. The chip was then washed and stained, and
scanned immediately using an Illumina BeadArray reader.
GenomeStudio software which was used to identify regions with
loss of heterozygosity (LOH) and/or copy number changes in
unpaired sample mode DNA.
In order to verify the Illumina array results, 100 ng DNA from
two sessile serrated adenoma samples were analysed using the
Affymetrix OncoScan FFPE Express service utilising Affymetrix
whole genome molecular inversion probe (MIP) SNP arrays. Data
were analysed using GoldenHelix SNP & Variation Suite 7
utilising the copy number analysis function.
Microsatellites (D4S230, D4S418, D4S914, D4S616, D4S1593,
D4S2289 and AFM112XD4) were chosen to cover the region of
interest comprising chromosome bands 4p15.1–4p15.31
(Chr4:18,500,000–35,500,000, Genome Build 36). PCR products
from the SAs (Text S1) underwent capillary electrophoresis
fragment analysis on an Applied Biosystems 3730xl analyser. In
the absence of paired normal DNA, we exploited the fact that the
SA samples contained a small amount of contaminating normal
cells and hence did not show complete LOH. On this basis, we
were able to analyse unpaired samples of normal colonic mucosa
with the same genotypes as the tumours for scoring LOH. In order
to verify the levels of heterozygosity in our study against previously
observed population norms for microsatellite markers, we also
carried out microsatellite PCR for all analysed microsatellites on
96 blood derived DNA controls from the CORGI study (primers
and conditions available in Text S1). Data were analysed using
Applied Biosystems GeneMapper 4.0 software. Samples were
called as having LOH if the peak area ratio of the second allele
compared to the first was less than 0.5 or greater than 2.0.
For methylation-specific PCR (MS-PCR) & pyrosequencing,
1 mg genomic DNA was bisulphite converted using the Zymo
DNA Methylation Gold bisulphite conversion kit and eluted into a
20 mL volume, which was then diluted to give a final concentration
of 20 ng/ml. MS-PCR primers (conditions in Text S1) were
designed using MethPrimer to span the CpG Island of the PCDH7
promoter and the SLIT2 promoter region [24] (primers and
conditions available in Text S1). After MS-PCR, SA sample
reaction products were run on a 2% agarose gel alongside those
from unpaired normal colonic mucosa DNA, 100% methylated
DNA and 100% unmethylated DNA as controls. Samples were
classed as methylated if a band was visualised in the methylation-
Table 2. Pyrosequencing results, with median methylation of normal tissue shown at bottom.
SLIT2 pyrosequencing of MSP site Long range SLIT2
Sample Tissue type Location CpG1 CpG2 CpG3 CpG4 CpG5 Average methylation
Serrated adenomas SSA/P Caecum 22% 70% * 35% * 51% * 26% * 10%
SSA/P Rectum 35% * 61% * 48% * 48% * 0% 0%
TSA Caecum 33% * 33% 29% 0% 21% * 9%
SSA/P Rectum 36% * 64% * 49% * 84% * 0% 0%
100% methylated Human control DNA - 83% * 88% * 82% * 94% * 91% * 85%
Caecal polyp Adenoma with low grade dysplasia Caecum 19% 22% 15% 23% 14% -
Normal mucosa Normal mucosa Ascending colon 29% * 36% * 17% 38% 18% -
Normal mucosa Transverse colon 9% 15% 11% 14% 10% -
Normal mucosa Left colon 16% 29% 0% 32% 17% -
Normal mucosa Descending colon 16% 17% 20% 26% 9% -
Normal mucosa Sigmoid 11% 14% 10% 13% 9% -
Normal mucosa Rectum 14% 14% 13% 17% 8% -
Normal mucosa Distal rectum 11% 19% 18% 36% 13% -
Cell lines C80 - 100% * 91% * 93% * 100% * 67% * -
HDC57 - 93% * 69% * 67% * 97% * 66% * -
LOVO - 79% * 90% * 90% * 100% * 71% * -
C99 - 95% * 90% * 88% * 100% * 74% * -
LS123 - 100% * 87% * 94% * 100% * 56% * -
CACO2 - 96% * 91% * 94% * 100% * 68% * -
HDC82 - 84% * 80% * 92% * 100% * 67% * -
COLO741 - 46% * 52% * 67% * 73% * 46% * -
LS411 - 40% * 38% * 36% * 42% 23% * -
CCK81 - 87% * 90% * 92% * 100% * 70% * -
SNU175 - 64% * 60% * 80% * 96% * 64% * -
Median Normal tissue 16% 19% 15% 25% 13% -
SD Normal tissue 6% 8% 6% 9% 4% -
2SD+median Normal tissue 28% 34% 30% 43% 20%
Asterisks indicate hypermethylation (.2SD from median).
doi:10.1371/journal.pgen.1003488.t002
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specific reaction and unmethylated if no band was present in the
methylated reaction but was present in the unmethylated reaction.
If there was a band in both samples, the sample was said to be
methylated as this could represent either hemi-methylation or
heterogeneity for methylation within the sample. If there were no
bands in either sample, the sample was said to have failed. It was
thought that MSP would provide an adequate method due to use of
highly sensitive and specific PCR reagents (Qiagen Multiplex PCR
kit), the low number of cycles used in the PCR reaction (35 cycles)
and previous studies documenting the reasonable sensitivity and
specificity of MSP [25–27]. However, to verify the results, bisulfite
pyrosequencing primers (primer sequences available in Text S1)
were designed to sequence the region of interest using Pyromark
Assay Design v2.0 (Qiagen). A off-the-shelf primer set for the SLIT2
CpG island (PM00018634), available from Qiagen, was also used to
analyse long range methylation of SLIT2. A bisulfite pyrosequenc-
ing PCR was set up with standard conditions (available in Text S1)
and carried out on a limited subset of samples. Products were
analysed using a PyroMark Q96 instrument.
To analyse BRAF mutation status, 20 ng of SA DNA was used
in a standard sequencing PCR reaction for the region surrounding
BRAF codon 600, and sequenced using an ABI BigDye
sequencing reaction (primers & conditions available in Text S1).
4 mM serrated adenoma sections were cut from FFPE blocks
and mounted on poly-L-lysine glass slides for use in immunohis-
tochemistry. Immunohistochemistry for PCDH7 was performed
using an indirect method against the primary antibody (Sigma
Prestige rabbit anti-PCDH7 (ID HPA011866), 1:100 dilution or
Sigma Prestige rabbit anti-SLIT2 (ID HPA023088, 1:35 dilution)
for 1 hr. A positive control of normal colonic mucosa obtained
from a normal screening colonoscopy of an individual without
colorectal tumours or a family history of colorectal cancer was
used, and the negative control was an SA which followed all
staining steps except application of the primary antibody.
Additional comparison was made with 100 classical colonic
adenomas was made using an in-house tissue microarray and
with 5 normal colonic tissue samples.
PCDH7 and SLIT2 IHC slides were read by two independent
assessors (see Acknowledgements). From normal tissue in this
study, expression of both PCDH7 and SLIT2 was found to be
primarily cytoplasmic, as previously observed by the Human
Protein Atlas project. IHC scoring was graded from 0–3 (0= no
expression, 1=mild expression, 2=moderate expression,
3 = heavy expression) as compared to the normal control (heavy
expression) and the median of the two observers was calculated. If
there was any disagreement, the higher expression value was used,
as this was conservative, based on an assumption that loss of
expression would be functionally important. Assessment of inter-
observer variation was estimated using Cohen’s Kappa (k).
As part of a separate independent experiment [13], paired
colorectal tumour and normal mucosa was also analysed for whole
genome methylation patterns on the Illumina HumanMethyla-
tion27 platform and subjected to analysis via Gene Set Enrich-
ment Analysis(GSEA).
Statistical analyses were carried out using STATA 11.1
(StataCORP, Texas). For the SLIT2 and PCDH7 protein
expression, variables were dichotomised into strong/moderate
expression (2 or 3), or no/weak expression (0 or 1). For all
comparisons, we used the x2 test, or Fisher’s exact test if any cell
within the table had a count of less than five.
Figure 5. Image of IHC stains for SLIT2. (a) Image of IHC stain for SLIT2 on mixed serrated/adenomatous polyp. Dotted line shows demarcation
between serrated and adenomatous crypts. Top right of image shows normal expression (adenomatous area). Bottom left of image shows loss of
expression (serrated area). (b) Image of IHC stain for SLIT2 on pure serrated area of mixed polyp to demonstrate serrated morphology.
doi:10.1371/journal.pgen.1003488.g005
Figure 4. Photomicrographs. (a) Photomicrographs of IHC staining for PCDH7 and SLIT2 in normal colonic mucosa, colonic adenoma and serrated
adenoma tissue. Expression of both PCDH7 and SLIT2 are shown by brown staining in the image. (b) 56, 106and 206photomicrographs of SLIT2 &
PCDH7 expression in serrated adenomas. Expression of both PCDH7 and SLIT2 are shown by brown staining in the image.
doi:10.1371/journal.pgen.1003488.g004
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Supporting Information
Text S1 Protocols for SLIT2 MSP, SLIT2 pyrosequencing,
BRAF sequencing and 4p15 microsatellite PCR.
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